key: cord-0764047-mm4kgvt1
authors: Starace, Michela; Iorizzo, Matilde; Sechi, Andrea; Alessandrini, Aurora Maria; Carpanese, Miriam; Bruni, Francesca; Vara, MD Giulio; Apalla, Zoe; Asz-Sigall, Daniel; Barruscotti, Stefania; Camacho, Francisco; Doche, Isabella; Estrada, Bruna Duque; Dhurat, Rachita; Gavazzoni, Maria Fernanda; Grimalt, Ramon; Harries, Matthew; Ioannidis, Dimitrios; McMichael, Amy; Melo, Daniel Fernandes; Oliveira, Rui; Ovcharenko, Yuliya; Pirmez, Rodrigo; Ramot, Yuval; Rudnicka, Lidia; Shapiro, Jerry; Silyuk, Tatiana; Sinclair, Rodney; Tosti, Antonella; Vano-Galvan, Sergio; Piraccini, Bianca Maria
title: Trichodynia and telogen effluvium in COVID-19 patients - results of an international expert opinion survey on diagnosis and management
date: 2021-08-03
journal: JAAD Int
DOI: 10.1016/j.jdin.2021.07.006
sha: 56ac8dc5af68481117bf1d5c30fc53ac43339dbb
doc_id: 764047
cord_uid: mm4kgvt1

Background Cutaneous manifestations of COVID-19 may be useful disease markers and prognostic indicators. Recently, post-infectious telogen effluvium and trichodynia have also been reported. Objective To evaluate the presence of trichodynia and telogen effluvium in patients with COVID-19 and describe their characteristics in relation to other signs and symptoms of the disease. Methods Patients with a history of COVID-19 presenting to the clinics of a group of hair experts because of telogen effluvium and/or scalp symptoms, were questioned with regards about their hair signs and symptoms in relation to the severity of COVID-19 and associated symptoms. Results Data from 128 patients were collected. Telogen effluvium was observed in 66.3% of patients and trichodynia in 58.4%. Trichodynia was associated to telogen effluvium in 42.4% of cases and was associated to anosmia and ageusia in 66.1% and 44.1% of cases, respectively. In the majority of patients (62.5%), hair signs and symptoms started within the first month post-COVID-19 diagnosis and in 47.8% of patients after 12 weeks or more. Limitations Recruitment of patient in specialized hair clinics, lack of a control group, and lack of recording of patient comorbidities. Conclusion The severity of the post-viral telogen effluvium observed in patients with a history of COVID-19 infection is influenced by COVID-19 severity. We identified an early onset (<4 weeks) and a late onset (>12 weeks) telogen effluvium.

In total, data of 128 adult patients, 24 males and 104 females, presenting with TE and/or TR were 151 collected and analyzed. To summarize the data coming from the 4-consecutive surveys, a median of 152 the reported percentages and numerical values was computed. 153

In decreasing order, morbilliform (33.3%), urticarial (21.4%), erythema polymorphous-like (20%), 154 chickenpox like (20%) and purpuric (16.7%) rashes were observed in this group of patients. Less 155 common findings were herpes zoster virus reactivation (13.3%) and atopic flares (6.7%). TE was 156 observed in 66.3% (84/128) of cases and TR in 58.4% (74/128). In 42.4% of cases TE and TR were 157 associated. TR was reported as one or more of the following: itching (37.6%), burning (34.7%), pain 158 (26.7%), paresthesia (4.9%) and it was grades as severe in 32% of cases. The most common reported 159 signs and symptoms of COVID-19 observed in patients with TE/TR were: fever (75.2%), anosmya 160 (57.4) cough (55.8%), dysgeusia (41.6%), asthenia (28.7%) headache (23.8%), myalgia (10.9%), 161 coryza (9.9%), dyspnea (7.9%), and diarrhea (5.9%) ( Table 1) . Relief of TR was achieved in 44% of 162 cases, in particular by sleeping (20.3%), washing with warm or cold water (13.5%), applying high-163 potency topical steroids (11.8%), combing (6.7%), massaging (3.3%), scratching (1.7%). Among 164 patients referring TE, 47.8% of patients witnessed a reactive TE, starting from 12 weeks or more 165 after the diagnosing of the infection, whereas the 52.2% witnessed an early onset TE. Only 69.7% 166 of patients with TE/TR received treatments: high potency topical steroids (50%), supplements with 167 amino acids and vitamin B complex (27%), topical minoxidil (15%) and pain relief lotions or hair 168 growth promoters (10%). 169

Among the 128 patients, the authors were able to provide detailed data about TR/TE only in 101 of 170 them and in particular 34 cases of TR alone (TR+/TE-), 42 cases of TE alone (TE+/TR-) and 25 cases 171 sample of 563 surveyed individuals forced at home due to quarantine (17), while another found an 196 increase in searches for the keywords "hair loss" by querying google trend (16). Some authors 197 attributed the possible worsening of a pre-existing TE to the psychosocial stress inflicted by the 198 quarantine imposed on the people by the government (15). However, the presence of emotional 199 stress is not an indisputable proof that stress incited the patient's hair loss. This relationship may 200 also be the inverse. 201 TE is a frequent cause of hair loss and is characterized by an acute or chronic diffuse shedding of 202 hair (20-21). It may be associated with TR, a painful sensation of the scalp upon touching or brushing 203 through the hair. Acute TE undergoes remission within 3-6 months of onset, unless associated with 204 androgenetic alopecia; while chronic TE persists beyond 6 months. Different alterations of the hair 205 cycle have been proposed as pathogenetic mechanism underlying TE. Headington (22) proposed 5 206 functional types of acute TE based on alternations in particular phases of the follicular cycle: 207 immediate or delayed anagen release, short anagen syndrome, immediate or delayed telogen 208 release. Several triggers such as drugs, trauma, and emotional and physiological stress can lead to 209 the development of acute TE. Chronic TE has been proposed to be due to a persistent reduction in 210 the variance of anagen duration (23). In around 33% of the cases, the cause of chronic TE remains 211 unknown (24). 212

In post COVID-19 infection-TE, it has been suggested that the viral insult might induce TE through 213 an immediate anagen release. Post-infectious hair loss has traditionally been categorized as acute 214 metalloproteinases 1 and 3) on the matrix cells of the hair follicle (12). 221 222 High levels of interleukin 6 have been associated to asthenia (25) that in our study was a strong 223 independent predictor of TE+/TR+ on bivariate logistic analysis, whether the comparison group was 224 High levels of interferons have also been associated with acute TE (13), metalloproteinases 1 and 3 229 and interleukin 1b with the hair follicle growth inhibition (26), and interleukin-6 with the induction 230 of the catagen phase (27). 231

We noticed, that 100% of patients belonging to the TR+/TE+ group and 23.8% of the TE+ group 232 developed a hair loss before 12 weeks, with a median latency period of 3 vs. 13 weeks among the 233 groups. We hypothesized that an immune-mediated microthrombotic reaction at the level of the 234 hair follicle vessels, or a direct infection of the hair follicle by the virus, result in inflammation and 235 cell death though evidence for this has as yet not been provided by histopathological examination. 236

The coagulation cascade, activated in response to COVID-19 infection, is responsible for a decreased 237 concentration of anticoagulant proteins due to reduced production and increased consumption. 238

These factors can induce microthrombi formation, which may occlude hair follicle blood supply. Another important consideration is that the majority of patients with COVID-19 were under 247 psychological and physiologic stress, both potential triggers for TE and TR. 248 TR is not specific for TE and has been associated with androgenetic alopecia and with psychological 249 illnesses, such as depression, obsessive personality disorder, and anxiety (29). In the past, it has 250 been demonstrated that TR does not correlate with activity of the hair loss (30). The only valid 251 information on TR is a correlation with the increased neuropeptide substance P expression (31). 252

Substance P is a stress-related neuronal peptide released by the nerve terminals that represents a 253 key factor in neuroinflammation, leading to the release of neuronal mediators implicated in 254 neuropathic pain, as could occur in the scalp related with hair loss. Substance P may also play a role 255 in hair cycle modification mediated by stress: stress seems to influence the relationship of substance 256 P with mast cells through neurokinin-1 (NK-1) receptors. Moreover, substance P has been associated 257 to sleep deprivation. During the COVID-19 pandemic people experienced greater anxiety caused by 258 the fear of the disease, worries about the outcomes of the pandemic, family loss and personal 259 uncertainty about the future that had a significant impact on sleep. The sum of increased stress, 260 frequent hair wash to avoid virus transmission and sleep disorders can result in TR more or less 261 associated with hair loss (32). Interestingly, in our sample, anosmya correlated with TR+/TE-both 262 on multivariate and univariate analysis, whereas dysgeusia correlated with TE+/TR+ in multivariate 263 analysis. Overall, both anosmya and dysgeusia largely prevailed in TR+ patients, possibly suggesting 264 a neurogenic role in this condition. Substance P is also a mediator of the sterile inflammation of the 265 dura mater, which has been considered to be the source of migraine pain. Substance P, together 266 with calcitonin gene-related peptide, leads to a cascade of inflammatory tissue responses including 267 arteriolar vasodilation, plasma protein extravasation, and degranulation of mast cells in their 268 peripheral target tissue (33). According to our data, headache showed in fact a positive correlation 269 with TR+. 270

Our analysis demonstrated that patients with a recent history of COVID-19 infection may consult a 272 hair specialist for a post-infection effluvium of early or late onset, with or without associated TR. In 273 addition to the typical acute TE occurring 3 to 4 months after an infection, we observed an early 274 onset effluvium occurring within less than 2 months post-infection. TR, when present, is related to 275 anosmya, ageusia and headache. We hypothesize that early hair shedding could be related to direct 276 injury from the virus and in particular due to immune-mediated microthrombotic events within the 277 follicular vasculature and the cytokine storm. The histopathological evidence is as yet pending. 278

This study has, however, several limitations including that the survey and the enrollment of patients 279 were conducted on a selected population not representative of the general population. Our data 280 did not include all patients affected by COVID-19 but only those patients who specifically seek for a 281 hair expert dermatologist for a medical advice about their hair signs and symptoms. 282

Other limitations of our study were lack of a control group, and lack of recording of patient 283 comorbidities that can induced telogen effluvium or trichodynia. 284

The aim of the study was however not to present data about the prevalence of TE and TR in COVID-285 19 general population, but to describe the occurrence of hair findings in patients with a history of Collected data were error checked and coded before entered in the computer database. 593

Frequencies, median, interquartile range were used to summarize qualitative and quantitative data, 594 respectively. Association between categorical variables was tested using the Chi square test. 595 Student T test for independent means or Mann-Whitney test were used to compare scale variables, 596 according to the parametric/nonparametric distribution, which was assessed by the Kolmogorov-597

Smirov and Shapiro-Wilk test. Subsequently, adjusted odds ratio (OR) with their 95% confidence 598 intervals (CI) from multivariate logistic regression were computed for variables common to the TE+, 599 TR+ and TE+/TR+ groups. A backward likelihood ratio (LR) method was chosen for variable selection. 600

The required assumptions of the logistic regression were checked with Hosmer and Lemeshow fit 601 test. Heteroschedasticity was assessed by the Breusch-Pagan Test. All statistical analysis were 602 performed using IBM®SPSS® Statistics for Windows, version 23 (IBM Corp., Armonk, N.Y., USA). 603

In total, data of 128 adult patients, 24 males and 104 females, presenting with TE and/or TR were 607 collected and analyzed. To summarize the data coming from the 4-consecutive surveys, a median of 608 the reported percentages and numerical values was computed. 609

In decreasing order, morbilliform (33.3%), urticarial (21.4%), erythema polymorphous-like (20%), 610 chickenpox like (20%) and purpuric (16.7%) rashes were observed in this group of patients. Less 611 common findings were herpes zoster virus reactivation (13.3%) and atopic flares (6.7%). TE was 612 observed in 66.3% (84/128) of cases and TR in 58.4% (74/128). In 42.4% of cases TE and TR were 613 associated. TR was reported as one or more of the following: itching (37.6%), burning (34.7%), pain 614 (26.7%), paresthesia (4.9%) and it was grades as severe in 32% of cases. The most common reported 615 signs and symptoms of COVID-19 observed in patients with TE/TR were: fever (75.2%), anosmya 616 (57.4) cough (55.8%), dysgeusia (41.6%), asthenia (28.7%) headache (23.8%), myalgia (10.9%), 617 coryza (9.9%), dyspnea (7.9%), and diarrhea (5.9%) ( Table 1) . Relief of TR was achieved in 44% of 618 cases, in particular by sleeping (20.3%), washing with warm or cold water (13.5%), applying high-619 potency topical steroids (11.8%), combing (6.7%), massaging (3.3%), scratching (1.7%). Among We noticed, that 100% of patients belonging to the TR+/TE+ group and 23.8% of the TE+ group 688 developed a hair loss before 12 weeks, with a median latency period of 3 vs. 13 weeks among the 689 groups. We hypothesized that an immune-mediated microthrombotic reaction at the level of the 690 hair follicle vessels, or a direct infection of the hair follicle by the virus, result in inflammation and 691 cell death though evidence for this has as yet not been provided by histopathological examination. 692

The coagulation cascade, activated in response to COVID-19 infection, is responsible for a decreased 693 concentration of anticoagulant proteins due to reduced production and increased consumption. 694

These factors can induce microthrombi formation, which may occlude hair follicle blood supply. 695

Drugs used to treat the infection may also play a role in the pathogenesis of TE, especially the late 696 onset one. Watras et al (28) highlighted the role of anticoagulants, including enoxaparin, in inducing studies on drug-related TE are represented by missing data regarding drug protocols: rapid change 700 of administered drugs and dose regimens as well as lack of standardized protocols provide too 701 fragmented data to be analyzed. 702

Another important consideration is that the majority of patients with COVID-19 were under 703 psychological and physiologic stress, both potential triggers for TE and TR. 704 TR is not specific for TE and has been associated with androgenetic alopecia and with psychological 705 illnesses, such as depression, obsessive personality disorder, and anxiety (29). In the past, it has 706 been demonstrated that TR does not correlate with activity of the hair loss (30). The only valid 707 information on TR is a correlation with the increased neuropeptide substance P expression (31). 708

Substance P is a stress-related neuronal peptide released by the nerve terminals that represents a 709 key factor in neuroinflammation, leading to the release of neuronal mediators implicated in 710 neuropathic pain, as could occur in the scalp related with hair loss. Substance P may also play a role 711 in hair cycle modification mediated by stress: stress seems to influence the relationship of substance 712 P with mast cells through neurokinin-1 (NK-1) receptors. Moreover, substance P has been associated 713 to sleep deprivation. During the COVID-19 pandemic people experienced greater anxiety caused by 714 the fear of the disease, worries about the outcomes of the pandemic, family loss and personal 715 uncertainty about the future that had a significant impact on sleep. The sum of increased stress, 716 frequent hair wash to avoid virus transmission and sleep disorders can result in TR more or less 717 associated with hair loss (32). Interestingly, in our sample, anosmya correlated with TR+/TE-both 718 on multivariate and univariate analysis, whereas dysgeusia correlated with TE+/TR+ in multivariate 719 analysis. Overall, both anosmya and dysgeusia largely prevailed in TR+ patients, possibly suggesting 720 a neurogenic role in this condition. Substance P is also a mediator of the sterile inflammation of the 721 dura mater, which has been considered to be the source of migraine pain. Substance P, together 722 with calcitonin gene-related peptide, leads to a cascade of inflammatory tissue responses including peripheral target tissue (33). According to our data, headache showed in fact a positive correlation 725 with TR+. 726

Our analysis demonstrated that patients with a recent history of COVID-19 infection may consult a 728 hair specialist for a post-infection effluvium of early or late onset, with or without associated TR. In 729 addition to the typical acute TE occurring 3 to 4 months after an infection, we observed an early 730 onset effluvium occurring within less than 2 months post-infection. TR, when present, is related to 731 anosmya, ageusia and headache. We hypothesize that early hair shedding could be related to direct 732 injury from the virus and in particular due to immune-mediated microthrombotic events within the 733 follicular vasculature and the cytokine storm. The histopathological evidence is as yet pending. 734

This study has, however, several limitations including that the survey and the enrollment of patients 735 were conducted on a selected population not representative of the general population. Our data 736 did not include all patients affected by COVID-19 but only those patients who specifically seek for a 737 hair expert dermatologist for a medical advice about their hair signs and symptoms. 738

Other limitations of our study were lack of a control group, and lack of recording of patient 739 comorbidities that can induced telogen effluvium or trichodynia. 740

The aim of the study was however not to present data about the prevalence of TE and TR in COVID-741 19 general population, but to describe the occurrence of hair findings in patients with a history of percentages, whereas quantitative variables are reported as median, followed by first and third 864 

neuro-related or caused by microinjuries remains to be determined

Dermatologists and primary care physicians should be aware of the possible presence of TR, alone 749 or associated to TE, in patients with a history of COVID-19 infection

A novel coronavirus from patients with pneumonia in China

Clinical features of patients infected with 2019 novel 757 coronavirus in Wuhan, China

Lesions during COVID-19 Pandemic: The State of the Art

Varicella-like exanthem as a specific COVID-761 19-associated skin manifestation: Multicenter case series of 22 patients

Skin manifestations in COVID-19 provide a clue for disease's 764 pathophysiology understanding

Skin manifestations of COVID-19: A worldwide review

Cutaneous Manifestations of COVID-19: An Evidence

What can the hair tell us about COVID-770 19?

Telogen effluvium associated with COVID-19 infection

A surge in the incidence of telogen effluvium in minority 774 predominant communities heavily impacted by COVID-19

Telogen effluvium: a sequela of COVID-19

SARS-CoV-2-induced 779 telogen effluvium: a multicentric study

Telogen effluvium related to post severe Sars

Cov-2 infection: Clinical aspects and our management experience

Acute telogen effluvium 785 associated with SARS-CoV-2 infection

Management of telogen effluvium during the COVID-19 emergency: 787 Psychological implications

Trichodynia is a distinguishing symptom of 794 telogen effluvium

Pathologic dynamics of human hair loss. 1. Telogen effluvium

Telogen Effluvium: Is There a Need for a New Classification? Skin Appendage

Telogen effluvium. New concepts and review

Chronic telogen effluvium is due to a reduction in the variance of 802 anagen duration

Diffuse hair loss in an adult female: Approach to diagnosis and 804 management

Fatigue and interleukin-6 -a multi-faceted relationship

Interleukin-1beta is differentially expressed by human dermal papilla 808 cells in response to PKC activation and is a potent inhibitor of human hair follicle growth in 809 organ culture

Interleukin-811 4 induces apoptosis in cultured human follicular keratinocytes, but not in dermal papilla 812 cells

Traditional Anticoagulants and Hair Loss: A Role for Direct Oral 814

The presence of trichodynia in patients with 63. Willimann B, Trüeb RM. Hair pain (trichodynia): frequency and relationship to hair loss and 818 patient gender

Substance P (SP) in innervated and non-innervated 820 blood vessels in the skin of patients with symptomatic scalp

The role of sleep in telogen effluvium and trichodynia: A 823 commentary in the context of the current pandemic

Substance P receptor antagonists in the therapy of migraine

Chi square, Student T-test, and Mann-Whitney test were performed as 865 appropriate

with TE associated to TR (TR+/TE+). Performing inferential statistical analysis, these 3 subgroups 628 differed significantly in the following factors: disease severity, ageusya, anosmya, headache, 629 asthenia and COVID-19 duration (p<0.05) (Figure 1 ). The TR+/TE+ group had a significantly shorter 630 COVID-TR latency onset as compared to TR+/TE-(1 vs 2 weeks, p <0.05), while the two groups did 631 not differ significantly in terms of TR duration (4 vs 5 weeks). The same trend was observed among 632 the TE+/TR-and TE+/TR+ groups, concerning the latency time-lapse (13 vs. 3 weeks, p<0.05) and TE 633 duration (9 vs. 8 weeks) (Figure 2 ). The TR+/TE+ was characterized by higher disease severity when 634 compared with TR+/TE-or TE+/TR-groups (p<0.05) (Figure 3) .